Literature DB >> 8702005

Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice.

E E Emeson1, M L Shen, C G Bell, A Qureshi.   

Abstract

T lymphocytes and monocyte/macrophages are prominent components of atherosclerotic lesions, and many of these cells are activated and secreting cytokines. To determine the role of these cells in the pathogenesis of atherosclerosis, we studied its development in T-cell-deficient mice fed a high fat atherogenic diet. Depleting euthymic mice of their CD4+ lymphocytes by 20 weekly injections of CD4 monoclonal antibodies reduced the mean area of their aortic lesions by approximately 70%. Similarly, the mean lesion area of T-cell-deficient nude (nu/nu) mice was 10% of the size of that of their heterozygote (nu/+) litter mates. Flow cytometric studies of splenic T cells and analyses of serum total and HDL cholesterol of these mice indicated that the differences in mean lesion areas among the experimental groups were most closely correlated with differences in splenic T cells content. These studies suggest that in these two models T lymphocytes contribute to the pathogenesis of early atherosclerotic lesions and that a further understanding of this phenomenon may provide future approaches toward the prevention and treatment of the disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8702005      PMCID: PMC1865332     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

1.  Abnormal distribution of T cell subsets in athymic mice.

Authors:  H R MacDonald; C Blanc; R K Lees; B Sordat
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

2.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

Review 3.  The pathogenesis of atherosclerosis--an update.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

4.  Immune-deficient mice develop typical atherosclerotic fatty streaks when fed an atherogenic diet.

Authors:  A I Fyfe; J H Qiao; A J Lusis
Journal:  J Clin Invest       Date:  1994-12       Impact factor: 14.808

5.  Cyclosporin-induced endothelial cell injury.

Authors:  C Zoja; L Furci; F Ghilardi; P Zilio; A Benigni; G Remuzzi
Journal:  Lab Invest       Date:  1986-10       Impact factor: 5.662

6.  An immunohistochemical analysis of human aortic fatty streaks.

Authors:  J M Munro; J D van der Walt; C S Munro; J A Chalmers; E L Cox
Journal:  Hum Pathol       Date:  1987-04       Impact factor: 3.466

7.  Quantitative assessment of atherosclerotic lesions in mice.

Authors:  B Paigen; A Morrow; P A Holmes; D Mitchell; R A Williams
Journal:  Atherosclerosis       Date:  1987-12       Impact factor: 5.162

8.  Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque.

Authors:  L Jonasson; J Holm; O Skalli; G Bondjers; G K Hansson
Journal:  Arteriosclerosis       Date:  1986 Mar-Apr

9.  Human atherosclerosis. II. Immunocytochemical analysis of the cellular composition of human atherosclerotic lesions.

Authors:  A M Gown; T Tsukada; R Ross
Journal:  Am J Pathol       Date:  1986-10       Impact factor: 4.307

10.  T lymphocytes in aortic and coronary intimas. Their potential role in atherogenesis.

Authors:  E E Emeson; A L Robertson
Journal:  Am J Pathol       Date:  1988-02       Impact factor: 4.307

View more
  35 in total

1.  Exogenous interferon-gamma enhances atherosclerosis in apolipoprotein E-/- mice.

Authors:  S C Whitman; P Ravisankar; H Elam; A Daugherty
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

Review 2.  Participation of innate and acquired immunity in atherosclerosis.

Authors:  L K Curtiss; N Kubo; N K Schiller; W A Boisvert
Journal:  Immunol Res       Date:  2000       Impact factor: 2.829

3.  The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice.

Authors:  A Daugherty; E Puré; D Delfel-Butteiger; S Chen; J Leferovich; S E Roselaar; D J Rader
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

4.  [Immunity and inflammation in atherosclerosis].

Authors:  D Wolf; K Ley
Journal:  Herz       Date:  2019-04       Impact factor: 1.443

5.  Diphtheria toxin-mediated ablation of lymphatic endothelial cells results in progressive lymphedema.

Authors:  Jason C Gardenier; Geoffrey E Hespe; Raghu P Kataru; Ira L Savetsky; Jeremy S Torrisi; Gabriela D García Nores; Joseph J Dayan; David Chang; Jamie Zampell; Inés Martínez-Corral; Sagrario Ortega; Babak J Mehrara
Journal:  JCI Insight       Date:  2016-09-22

Review 6.  Inflammation and immune system interactions in atherosclerosis.

Authors:  Bart Legein; Lieve Temmerman; Erik A L Biessen; Esther Lutgens
Journal:  Cell Mol Life Sci       Date:  2013-02-21       Impact factor: 9.261

7.  Lymphocyte subset characterization in patients with early clinical presentation of coronary heart disease.

Authors:  Natale Daniele Brunetti; Carmine D'Antuono; Michele Rana; Girolamo D'Arienzo; Luisa De Gennaro; Matteo Di Biase
Journal:  J Thromb Thrombolysis       Date:  2012-11       Impact factor: 2.300

Review 8.  Adaptive immunity and atherosclerosis: mouse tales in the AJP.

Authors:  Andrew H Lichtman
Journal:  Am J Pathol       Date:  2012-11-16       Impact factor: 4.307

9.  Mildly oxidized low-density lipoproteins decrease early production of interleukin 2 and nuclear factor kappaB binding to DNA in activated T-lymphocytes.

Authors:  S Caspar-Bauguil; J Tkaczuk; M J Haure; M Durand; J Alcouffe; M Thomsen; R Salvayre; H Benoist
Journal:  Biochem J       Date:  1999-01-15       Impact factor: 3.857

10.  Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.

Authors:  Carlos Borelli Zeller; Simone Appenzeller
Journal:  Curr Cardiol Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.